A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.
Multi-technology tumor profiling changed recommended treatments for three-quarters of ovarian cancer patients, with earlier therapy linked to improved survival.
This study demonstrates clinical feasibility of 11-technology comprehensive multimodal profiling (DNA, RNA, protein, and functional assays) for HGSOC within a clinically actionable 4-week window, finding that profiling changed recommended treatments for 76% of patients and that multi-omics-guided maintenance therapy correlated with improved overall survival. Single-cell analysis of ascites-derived cancer cells revealed marked heterogeneity increase after chemotherapy and distinct molecular profiles versus solid tumor, suggesting that molecularly guided adjuvant therapy prior to chemotherapy may be the more impactful application.
What the study was
- Study design
- Clinical feasibility study with multimodal molecular profiling (11 technologies within 4-week turnaround)
- Population
- Women with high-grade serous ovarian cancer receiving chemotherapy
- Category
- Genomics/Precision Medicine
- Maturity
- Potentially Practice-Changing
- Journal
- Nature communications
Why it surfaced
Clinical feasibility demonstration of comprehensive multimodal profiling in HGSOC, a cancer with poor prognosis and limited personalized options; 76% treatment recommendation change rate and OS association with multi-omics guidance justify prospective testing of profiling-driven adjuvant treatment in HGSOC.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.